OXFORD, Miss., May 9, 2007 (PRIME NEWSWIRE) -- Insight Medical Group, a bioscience technology development and acquisition company specializing in the accurate detection of cancer, announced today it has appointed Dr. Kary Mullis, Ph.D., to its Board of Advisors.
Dr. Mullis received a Nobel Prize in chemistry in 1993 for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the twentieth century. A method of amplifying DNA, PCR multiplies a single, microscopic strand of the genetic material billions of times within hours. The process has multiple applications in medicine, genetics, biotechnology and forensics.
Dr. Mullis has authored several major patents. His patented inventions include the PCR technology and UV-sensitive plastic that changes color in response to light. His most recent patent application covers a revolutionary approach for instantly mobilizing the immune system to neutralize invading pathogens and toxins, leading to the formation of his latest venture, Altermune LLC.
Dr. Mullis was awarded the Japan Prize in 1993 for the PCR invention. It is one of international science's most prestigious awards.
His many other awards include the Thomas A. Edison Award (1993); California Scientist of the Year Award (1992); the National Biotechnology Award (1991); the Gairdner Award, Toronto, Canada (1991); the R&D Scientist of the Year (1991); the William Allan Memorial Award of the American Society of Human Genetics (1990); and the Preis Biochemische Analytik of the German Society of Clinical Chemistry and Boehringer Mannheim (1990). Dr. Mullis was presented the honorary degree of Doctor of Science from the University of South Carolina in 1994. He was inducted into the National Inventors Hall of Fame in 1998. He also was awarded an honorary doctor of science degree from the University of Bologna, Italy.
His many publications include "The Cosmological Significance of Time Reversal" (Nature), "The Unusual Origin of the Polymerase Chain Reaction" (Scientific American), "Primer-directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase" (Science), and "Specific Synthesis of DNA In Vitro via a Polymerase Catalyzed Chain Reaction" (Methods in Enzymology).
Dr. Mullis has written an autobiography, "Dancing Naked in the Mind Field," published by Pantheon Books in 1998.
He is currently a Distinguished Researcher at Children's Hospital and Research Institute in Oakland, California.
Anthony Welch, Chairman, said: "Dr. Mullis's decision to join our advisory board brings us joy and heralds a bright future. His presence inspires us to greatness and furthers the credibility of the science and technology behind our cancer detection system."
Dr. Mullis said, "After decades of neglect by most established researchers -- exceptions being Drs. Duesberg and Rasnick -- the aneuploidy theory of carcinogenesis has finally resumed center stage in cancer diagnosis. We are expecting Insight Medical Group to be a major player in this resurgence."
About the AnuCyte Cancer Detection System
The AnuCyte Cancer Detection System is an automated machine to detect the presence of cancer in cell samples. The system accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test within the same sample. The system is designed based on the chromosomal imbalance theory of cancer. The science behind the company's cancer detection technology is of the very highest standard. Over the prior ten years the chromosomal imbalance theory of cancer has been proven correct both experimentally and theoretically in numerous, rigorously peer-reviewed publications in the leading journals.
About Insight Medical Group and Modern Technology Corp.
Insight Medical Group, a wholly owned subsidiary of Modern Technology Corp., is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The AnuCyte Cancer Detection System was invented by Dr. David Rasnick, Ph.D. The technology behind AnuCyte and the chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, Ph.D. and Dr. Peter Duesberg, Ph.D., who continues his studies on cancer research at the University of California, Berkeley. Modern Technology Corp., a bioscience technology development and acquisition company, builds revenues through a model continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC is a fully reporting public company with the U.S. Securities and Exchange Commission. For the company's SEC filings, visit www.sec.gov. The company's web address is: http://www.moderntechnologycorp.com.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.